18-60371598-ATC-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_StrongPP5_Very_Strong
The NM_005912.3(MC4R):c.750_751delGA(p.Ile251fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000328 in 1,614,122 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000034 ( 0 hom. )
Consequence
MC4R
NM_005912.3 frameshift
NM_005912.3 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.70
Genes affected
MC4R (HGNC:6932): (melanocortin 4 receptor) The protein encoded by this gene is a membrane-bound receptor and member of the melanocortin receptor family. The encoded protein interacts with adrenocorticotropic and MSH hormones and is mediated by G proteins. This is an intronless gene. Defects in this gene are a cause of autosomal dominant obesity. [provided by RefSeq, Jan 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 12 pathogenic variants in the truncated region.
PP5
Variant 18-60371598-ATC-A is Pathogenic according to our data. Variant chr18-60371598-ATC-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 435828.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr18-60371598-ATC-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MC4R | NM_005912.3 | c.750_751delGA | p.Ile251fs | frameshift_variant | 1/1 | ENST00000299766.5 | NP_005903.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MC4R | ENST00000299766.5 | c.750_751delGA | p.Ile251fs | frameshift_variant | 1/1 | 6 | NM_005912.3 | ENSP00000299766.3 | ||
ENSG00000285681 | ENST00000650201.1 | n.113+42254_113+42255delTC | intron_variant | |||||||
ENSG00000285681 | ENST00000658928.1 | n.156+42254_156+42255delTC | intron_variant |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152230Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152230
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251364Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135844
GnomAD3 exomes
AF:
AC:
9
AN:
251364
Hom.:
AF XY:
AC XY:
1
AN XY:
135844
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000342 AC: 50AN: 1461892Hom.: 0 AF XY: 0.0000248 AC XY: 18AN XY: 727248
GnomAD4 exome
AF:
AC:
50
AN:
1461892
Hom.:
AF XY:
AC XY:
18
AN XY:
727248
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152230Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74380
GnomAD4 genome
AF:
AC:
3
AN:
152230
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74380
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 22, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this premature translational stop signal affects MC4R function (PMID: 12970296, 15126516, 20462274). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. ClinVar contains an entry for this variant (Variation ID: 435828). This premature translational stop signal has been observed in individual(s) with early-onset obesity (PMID: 12970296, 15126516, 20966905). It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs13447339, gnomAD 0.08%). This sequence change creates a premature translational stop signal (p.Ile251Trpfs*34) in the MC4R gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 82 amino acid(s) of the MC4R protein. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 08, 2023 | Published functional studies demonstrate loss of MC4R function (PMID: 12970296, 20462274); Frameshift variant predicted to result in abnormal protein length as the last 82 amino acids are replaced with 33 different amino acids, and other similar variants have been reported in HGMD; This variant is associated with the following publications: (PMID: 20462274, 15126516, 12970296, 34045736) - |
BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 18, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | May 01, 2004 | - - |
Obesity, autosomal dominant Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jul 29, 2016 | - - |
Obesity Pathogenic:1
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 22, 2020 | The p.Ile251Trpfs variant in MC4R has been reported in six North African individuals with obesity, segregated with disease in these six affected relatives from one family (PMID: 15126516), and has been identified in 0.08% (8/10366) of Ashkenazi Jewish chromosomes, 0.004% (1/24968) of African chromosomes, and 0.0008% (1/129092) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs13447339). This variant has also been reported in ClinVar as pathogenic (Variation ID: 435828). In vitro functional studies provide some evidence that the p.Ile251Trpfs variant may impact protein function (PMID: 15126516). However, these types of assays may not accurately represent biological function. This variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at position 251 and leads to a premature termination codon 34 amino acids downstream. This alteration is then predicted to lead to a truncated protein since this is a single exon gene that is not predicted to undergo nonsense mediated decay. Heterozygous loss of function of the MC4R gene is an established disease mechanism in obesity. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PVS1_moderate, PP1_moderate, PS3_moderate (Richards 2015). - |
MC4R-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 13, 2024 | The MC4R c.750_751delGA variant is predicted to result in a frameshift and premature protein termination (p.Ile251Trpfs*34). This variant has been reported in the heterozygous and homozygous states in individuals with obesity (see, for example, Lubrano-Berthelier et al. 2004. PubMed ID: 15126516; Welling et al. 2021. PubMed ID: 34291582; Zaitoon et al. 2023. PubMed ID: 37160786). In one family, the heterozygous parents and siblings were described as less severely affected than the homozygous proband (Lubrano-Berthelier et al. 2004. PubMed ID: 15126516). Functional characterization also revealed that this variant abolishes MC4R activity (Table 1, Hinney et al. 2003. PubMed ID: 12970296; Lubrano-Berthelier et al. 2004. PubMed ID: 15126516; Xiang et al. 2010. PubMed ID: 20462274). This variant is reported in 0.077% of alleles in individuals of Ashkenazi Jewish descent in a large population database. Frameshift variants in MC4R are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at